98 related articles for article (PubMed ID: 31846712)
1. Targeting heme-oxidized soluble guanylate cyclase to promote osteoblast function.
Tesfamariam B
Drug Discov Today; 2020 Feb; 25(2):422-429. PubMed ID: 31846712
[TBL] [Abstract][Full Text] [Related]
2. BAY58-2667 Activates Different Soluble Guanylyl Cyclase Species by Distinct Mechanisms that Indicate Its Principal Target in Cells is the Heme-Free Soluble Guanylyl Cyclase-Heat Shock Protein 90 Complex.
Dai Y; Stuehr DJ
Mol Pharmacol; 2023 May; 103(5):286-296. PubMed ID: 36868790
[TBL] [Abstract][Full Text] [Related]
3. Factors influencing the soluble guanylate cyclase heme redox state in blood vessels.
Tawa M; Okamura T
Vascul Pharmacol; 2022 Aug; 145():107023. PubMed ID: 35718342
[TBL] [Abstract][Full Text] [Related]
4. Thiol-Based Redox Modulation of Soluble Guanylyl Cyclase, the Nitric Oxide Receptor.
Beuve A
Antioxid Redox Signal; 2017 Jan; 26(3):137-149. PubMed ID: 26906466
[TBL] [Abstract][Full Text] [Related]
5. Redox regulation of soluble guanylyl cyclase.
Shah RC; Sanker S; Wood KC; Durgin BG; Straub AC
Nitric Oxide; 2018 Jun; 76():97-104. PubMed ID: 29578056
[TBL] [Abstract][Full Text] [Related]
6. The Role of sGC Stimulators and Activators in Heart Failure With Reduced Ejection Fraction.
Cordwin DJ; Berei TJ; Pogue KT
J Cardiovasc Pharmacol Ther; 2021 Nov; 26(6):593-600. PubMed ID: 34487435
[TBL] [Abstract][Full Text] [Related]
7. NO rapidly mobilizes cellular heme to trigger assembly of its own receptor.
Dai Y; Faul EM; Ghosh A; Stuehr DJ
Proc Natl Acad Sci U S A; 2022 Jan; 119(4):. PubMed ID: 35046034
[TBL] [Abstract][Full Text] [Related]
8. Replacement of heme by soluble guanylate cyclase (sGC) activators abolishes heme-nitric oxide/oxygen (H-NOX) domain structural plasticity.
Argyriou AI; Makrynitsa GI; Dalkas G; Georgopoulou DA; Salagiannis K; Vazoura V; Papapetropoulos A; Topouzis S; Spyroulias GA
Curr Res Struct Biol; 2021; 3():324-336. PubMed ID: 34901882
[TBL] [Abstract][Full Text] [Related]
9. The Novel, Clinical-Stage Soluble Guanylate Cyclase Activator BI 685509 Protects from Disease Progression in Models of Renal Injury and Disease.
Reinhart GA; Harrison PC; Lincoln K; Chen H; Sun P; Hill J; Qian HS; McHugh MC; Clifford H; Ng KJ; Wang H; Fowler D; Gueneva-Boucheva K; Brenneman JB; Bosanac T; Wong D; Fryer RM; Sarko C; Boustany-Kari CM; Pullen SS
J Pharmacol Exp Ther; 2023 Mar; 384(3):382-392. PubMed ID: 36507845
[TBL] [Abstract][Full Text] [Related]
10. Soluble guanylyl cyclase: A novel target for the treatment of vascular cognitive impairment?
Nelissen E; Schepers M; Ponsaerts L; Foulquier S; Bronckaers A; Vanmierlo T; Sandner P; Prickaerts J
Pharmacol Res; 2023 Nov; 197():106970. PubMed ID: 37884069
[TBL] [Abstract][Full Text] [Related]
11. Dental Pulp Inflammation Initiates the Occurrence of Mast Cells Expressing the α
Korkmaz Y; Plomann M; Puladi B; Demirbas A; Bloch W; Deschner J
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674416
[TBL] [Abstract][Full Text] [Related]
12. Smooth muscle cell CYB5R3 preserves cardiac and vascular function under chronic hypoxic stress.
Durgin BG; Wood KC; Hahn SA; McMahon B; Baust JJ; Straub AC
J Mol Cell Cardiol; 2022 Jan; 162():72-80. PubMed ID: 34536439
[TBL] [Abstract][Full Text] [Related]
13. Identification of new multi-substituted 1H-pyrazolo[3,4-c]pyridin-7(6H)-ones as soluble guanylyl cyclase (sGC) stimulators with vasoprotective and anti-inflammatory activities.
Kintos DP; Salagiannis K; Sgouros A; Nikolaropoulos SS; Topouzis S; Fousteris MA
Bioorg Chem; 2024 Mar; 144():107170. PubMed ID: 38335755
[TBL] [Abstract][Full Text] [Related]
14. Effects of soluble guanylate cyclase stimulator on renal function in ZSF-1 model of diabetic nephropathy.
Hu L; Chen Y; Zhou X; Hoek M; Cox J; Lin K; Liu Y; Blumenschein W; Grein J; Swaminath G
PLoS One; 2022; 17(1):e0261000. PubMed ID: 35085251
[TBL] [Abstract][Full Text] [Related]
15. Cellular Factors That Shape the Activity or Function of Nitric Oxide-Stimulated Soluble Guanylyl Cyclase.
Sharina I; Martin E
Cells; 2023 Feb; 12(3):. PubMed ID: 36766813
[TBL] [Abstract][Full Text] [Related]
16. Hsp90 in Human Diseases: Molecular Mechanisms to Therapeutic Approaches.
Sumi MP; Ghosh A
Cells; 2022 Mar; 11(6):. PubMed ID: 35326427
[TBL] [Abstract][Full Text] [Related]
17. Per-ARNT-Sim Domains in Nitric Oxide Signaling by Soluble Guanylyl Cyclase.
Montfort WR
J Mol Biol; 2024 Feb; 436(3):168235. PubMed ID: 37572934
[TBL] [Abstract][Full Text] [Related]
18. Low levels of nitric oxide promotes heme maturation into several hemeproteins and is also therapeutic.
Ghosh A; Sumi MP; Tupta B; Okamoto T; Aulak K; Tsutsui M; Shimokawa H; Erzurum SC; Stuehr DJ
Redox Biol; 2022 Oct; 56():102478. PubMed ID: 36116161
[TBL] [Abstract][Full Text] [Related]
19. Hemoglobin resident in the lung epithelium is protective for smooth muscle soluble guanylate cyclase function.
Sumi MP; Tupta B; Roychowdhury S; Comhair S; Asosingh K; Stuehr DJ; Erzurum SC; Ghosh A
Redox Biol; 2023 Jul; 63():102717. PubMed ID: 37120930
[TBL] [Abstract][Full Text] [Related]
20. Runcaciguat, a novel soluble guanylate cyclase activator, shows renoprotection in hypertensive, diabetic, and metabolic preclinical models of chronic kidney disease.
Bénardeau A; Kahnert A; Schomber T; Meyer J; Pavkovic M; Kretschmer A; Lawrenz B; Hartmann E; Mathar I; Hueser J; Kraehling JR; Eitner F; Hahn MG; Stasch JP; Sandner P
Naunyn Schmiedebergs Arch Pharmacol; 2021 Dec; 394(12):2363-2379. PubMed ID: 34550407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
